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Abstract
Background:  The ability to acquire fully human monoclonal antibodies (mAbs) with pre-defined
specificities is critical to the development of molecular tags for the analysis of receptor function in addition
to promising immunotherapeutics. Yet most of the arriving affinity maturated and complete human
immunoglobulin G (IgG) molecules, which are actually derived from single human B cells, have not widely
been used to study the conserved self antigens (Ags) such as CD152 (cytotoxic T lymphocyte antigen-4,
CTLA-4) because proper hosts are lacking.
Results: Here we developed an optimized protocol for site-directed in vitro immunizing peripheral blood
mononuclear cells (PBMC) by using a selected epitope of human CD152, an essential receptor involved in
down-regulation of T cell activation. The resultant stable trioma cell lines constantly produce anti-CD152
mAb (γ4λhuCD152), which contains variable (V) regions of the heavy chain and the light chain derived
from the VH3 and Vλ human germline genes, respectively, and yet displays an unusual IgG4 isotype.
Interestingly, γ4λhuCD152 has a basic pI not commonly found in myeloid monoclonal IgG4λs as revealed
by the isoelectric focusing (IEF) analysis. Furthermore, γ4λhuCD152 binds specifically, with nanomolar
affinity, to an extracellular constituency encompassing the putative second complementarity determining
region (CDR2) of CD152, whereby it can react to activated CD3+ cells.
Conclusion: In a context of specific cell depletion and conditioned medium,in vitro induction of human
Abs against a conserved self Ag was successfully acquired and a relatively basic mAb, γ4λhuCD152, with
high affinity to CDR2 of CD152 was thus obtained. Application of such a human IgG4λ mAb with
designated CDR2 specificity may impact upon and prefer for CD152 labeling both in situ and ex situ, as it
does not affect the binding of endogenous B7 ligands and can localize into the confined immunological
synapse which may otherwise prevent the access of whole IgG1 molecules.
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Background
Fueled by ever-growing demand, complete human mAbs
have become one of the most important disciplines for
obtaining research and therapeutic leads. Currently, the
identification of such materials with desired specificities
requires either selecting from artificial genetic Ig libraries
[1,2] or immunizing transgenic mice that harbored large
human Ig loci [3,4]. Unfortunately, because of their
dependence on Ig gene shuffling, information about the
original pairing of heavy (H) and light (L) chains inherent
in a single human B cell has been limited. An alternative
strategy for obtaining complete human mAbs would be to
use combined heterotopic B- and T-cell epitopes as an
immunogen in human lymphocyte cultures, followed by
standard hybridoma and/or cloning procedures. Initially,
the validity of this site-directed in vitro immunization
approach has been established in the procurement of
gp120-specific monoclonal IgM from seronegative, non-
infected lymphocytes [5]. Viral neutralizing, affinity mat-
urated and isotype switched IgG responses were subse-
quently confirmed in human naïve B lymphocytes [6-8].
However, from prior reports, it was unclear whether B-cell
epitopes present on a self-protein would also elicit signif-
icant IgG responses in the site-directed in vitro immuniza-
tion regimen; therefore, a molecule with its existence on
lymphocytes represents an ideal candidate for such a
study.
CD152 belongs to a group of immunomodulating recep-
tors, collectively termed as CD28 superfamily [9], and rep-
resents one of the major inhibitory receptors involved in
co-stimulatory pathways regulating both humoral and
cellular immune response [10,11]. These inhibitory
effects are due in part to a higher avidity of binding by the
common endogenous agonists, B7-1 (CD80) and B7-2
(CD86), compared with its stimulatory homologue,
CD28 [12,13]. The lurch toward CD152 of these agonists
reduces T-cell proliferation and cytokine production,
resulting in attenuated immune responses, and thus
mediates tolerance and/or anergy [14,15]. CD152 has
also been demonstrated to promote clonal anergy devel-
opment by limiting cell cycle progression during the pri-
mary response in vivo [16], thus CD152 opened up the
possibility to study whether the current knowledge in site-
directed in vitro immunization allows any generalizations
to be made that will consequently be useful in developing
human mAbs against self Ags.
Structural findings indicate that the CD152 protein is
composed of disulfide-linked homodimers of extracellu-
lar IgV domains. Each domain consists of two layered β-
sheets with ten strands (A, A', B, C, C', C", D, E, F and G)
[17-19]. Furthermore, one mutational [20] and two crys-
tallographic [17,18] studies have independently pointed
out that CDR1-like (the B-C loop) and CDR3-like (the F-
G loop) regions in CD152 directly bind B7 ligands,
whereas the role of CDR2 was very insignificant, if it
played a part at all. In contrast to the harmonized results
to the relative contribution of individual CDR's, a severe
discrepancy existed even in the span of CDR2. In the
mutational model, the extracellular consecutive
51AATYM55  motif was implicated to be CDR2 [20]
whereas co-crystallographic structures characterized the
C'-C" loop encompassing a single Met 55 as CDR2
[17,19]. To further complicate the picture of functionality,
the downstream M10 (59ELT61) and M11 (66SICT69)
epitopes, localized between the C" and D strands, have
been revealed to play an important pharmacological role
upon Ab binding [21]. Thus not only is the dimension of
CDR2 controversial but also, additional domains poten-
tially involved in certain functions of CD152 are sug-
gested. The suggestion of an important contribution in
this area defined by the Met 55 core
(51AATYMMGNELTFLDDSICT69) is further strengthened
by observing a considerable conservation across all iden-
tified CD152, with six of the 19 amino acids having iden-
tical residues to the human sequence [19].
Here we explored the stimulating effect of the Met 55-
cored sequence by invoking the optimized process of site-
directed in vitro immunization and somatic cell hybridiza-
tion [22] to target this particular area. We showed that
human Abs that are specific for the CDR2-encompassed
Met 55-cored region could be regularly generated in vitro
from normal donors after sensitization with a heterotopic
peptide. Moreover, the resultant human IgG4λ mAb is
useful to probe and label CDR152 in situ and ex situ dur-
ing the responses involving such a particular self mole-
cule.
Results
Procuring the desired Ab response by site-directed in vitro 
immunization and electrofusion
Plasma samples from repeated healthy donors were ini-
tially screened for IgG and IgM against tetanus toxoid,
rhCD152 and mouse IgG2a by ELISA. It was found that
no donors (0/17) had any significant IgM or IgG
responses to CD152; however, anti-tetanus toxoid IgG
(15/17) and some, albeit low, levels of specific IgG anti-
body against mouse IgG2a (2/17) were found. After pri-
mary and secondary in vitro immunization of five PBMC's
from individual donors, the respective EBV-activated lym-
phoblastoid cultures were screened for human Igs against
CD152. When assayed by ELISA, frequencies of specific
cultures detected in the lymphoblastoid cells after primary
in vitro immunization ranged from 0% to above 3% and
were significantly elevated when CD8+ and CD56+cells
were simultaneously removed before primary peptide
stimulation (Fig. 1A).BMC Biotechnology 2007, 7:51 http://www.biomedcentral.com/1472-6750/7/51
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As shown in Additional File 1, although there was not a
statistically significant increase, the removal of IL-10+ cells
before secondary peptide stimulation yielded the highest
frequency of specific IgG-producing cells.
Wells containing anti-CD152 IgG level that was five times
higher than anti-murine IgG2a were subsequently pooled
for electrofusion. One fusion yielded eleven clones secret-
ing anti-CD152 Abs. Three of them were subcloned and
found to be of the IgG4 isotype. To select a mAb for fur-
ther characterization, two parameters were taken into
account: the secretory capacity of the trioma, estimated
from the ELISA titer and the relative specificity, reflected
by the reactivities to other unrelated antigens such as teta-
nus toxoid, bovine serum albumin, and uncoated wells.
Figure 1B also demonstrates that the selected monoclonal
Anti-CD152 derived from site-directed in vitro immunization exhibits specific binding towards human CD152 expressed both  as a recombinant protein as well as a cell surface receptor Figure 1
Anti-CD152 derived from site-directed in vitro immunization exhibits specific binding towards human CD152 
expressed both as a recombinant protein as well as a cell surface receptor. Panel A summarizes specific responses of 
PBMC's from five subjects receiving primary Ag stimulation alone (Nil) or from PBMC's treated with the indicated regimen. 
Bars indicate the median value of all subjects analyzed. Filled triangles represent specific frequencies of individual PBMC's. Orig-
inal data can be retrieved from Additional File 1. Panel B illustrates a representative ELISA reactivity profile of culture superna-
tant. Diluted supernatants were tested in duplicate with 100 µL added to each well. Deviation between duplicate was less than 
10% for any reported value. Panel C represents immunofluorescent staining of mitogen-activated CD3+ T cells (right thick 
peaks). PBMCs were isolated from normal blood donors and stimulated with indicated mitogens for 72 h to induce CD152 
expression. Expression of mAb-recognized epitope was verified in gated CD3 population by flow cytometry. Data represent 
one experiment from three different normal subjects. Appropriate isotype controls were used for all Abs. The basal fluores-
cence obtained with the use of isotype control (IgG4λ myeloma protein) is indicated by the left thin peaks.
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had a near-background reaction with unrelated Ags. Long-
term (over a period of 60 months of continuous culture)
stable Ab production in a concentration above 4 µg/ml/
107  trioma cells in spent medium was consistently
observed.
Presentation of recognized epitope on mitogen-activated 
human T cells and the immunogen
To investigate whether the specificity observed in ELISA
was also applicable for the activated human T cells in situ,
we used the mitogen-dependent stimulation system,
where peripheral T cells were activated with anti-CD3,
PHA, ConA, or the combination of PMA/ionomycin or
PHA/PMA. CD152-expressing T cells were numerated in
CD3+ population by flow cytometry. After a 72-h culture
period, few CD3+ T cells without stimulation were stained
by our human mAb whilst a large number of
CD152+CD3+ T cells were constantly observed after activa-
tion with PMA and PHA (Fig. 1B). Control human IgG4λ
myeloma protein failed to distinguish among the activa-
tion statuses and the present mAb did not react with acti-
vated murine CD3+ T cells (data not shown).
To further characterize the nature of mAb binding,
epitope mapping was performed by the Western blotting
method with arrays containing the overlapping pende-
capeptides, encompassing CDR1-like (the B-C loop),
CDR3-like (the F-G loop) and the Met 55-cored sequence
localized between the C' and D strands of the CD152
extracellular portion. Figure 2 depicts that only the pep-
tide corresponding to the C-terminus of the Met 55-cored
sequence (54YMMGNELTFLDDSIC68) was best recognized
by the mAb while neither the promiscuous T-cell epitope,
nor CDR1-like or CDR3-like region contributes to the
binding. From this result, it can be concluded that the Ala
51, Ala 52, Thr 53 and Thr 69 are not essential for mAb
recognition.
Immunological and physicochemical properties of the mAb
The mAb was isotyped and subtyped by solid phase
ELISA, utilizing its reactivity with human CD152 and
appropriate immobilized typing Abs. The binding depicts
the simultaneous presence of γ4 and λ chains in the mAb
while other Ig chains are absent (Fig. 3A), thus the mAb
was termed as γ4λhuCD152. Additionally, to compare the
clonal nature with existing human monoclonal IgG1λ
and IgG4λ derived from purified myeloma proteins, the
isoelectric focusing (IEF) patterns were subsequently visu-
alized. The resolvable bands, as shown in Figure 3B, indi-
cate that γ4λhuCD152 has a slightly lower yet basic pI
similar to the IgG1λ, but in contrast to the acidic IgG4λ
myeloma protein or to the anionic (pI 4.5–5.0) species of
Immunoblot screening of peptide arrays denotes the mAb specificity against the Met 55-cored CDR2-like region of human  CD152 Figure 2
Immunoblot screening of peptide arrays denotes the mAb specificity against the Met 55-cored CDR2-like 
region of human CD152. 1 µg/mL of purified mAb was used to determine the binding epitope. Sequences of EYASPGKAT-
EVRVTV, KVELMYPPPYYLGIG and QYIKANSKFIGITEL indicate CDR1-encompassing region, CDR3-encompassing region and 
T cell epitope (italic) used for site-directed immunization, respectively.
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proteins commonly described for polyclonal IgG4 [24].
Western blot confirmed the purity of the Ab samples as
illustrated by the anti-λ staining configurations. As shown
in Figures 3B, the corresponding pI of the myeloid IgG1λ,
IgG4λ and γ4λhuCD152 obtained with linear regression
of pH gradient were 7.92–8.79, 5.76–6.52 and 7.87–8.41,
respectively.
The equilibrium dissociation constant (Kd) for the puri-
fied intact γ4λhuCD152 was determined by an IAsys anal-
ysis. The rate constant was evaluated directly from the
sensogram using five cycles of soluble mAb binding to the
immobilized CD152-muIg. Figure 3D reveals that, with
the analysis of extent and association in single phase, the
Kd was deduced to be 4 × 10-9 M.
Ig sequences
Following elelectrofusion and subsequent clonings, stable
trioma cells producing IgG4λ were selected and the cDNA
encoding the Ig variable regions were cloned and
sequenced. By comparing the VH with the available Ig
sequences, it was concluded that the VH, being 89.80%
(88/98) amino acid identity (Fig. 4A), is associated with
three human VH3 germline segments [GenBank:
AB019439, VH3–30 and VH3–33]. Alignments have also
disclosed homology of VL to three existing human Vλ
germline genes [GenBank: BAC01778, S78058 and
Immunological and biochemical natures of the mAb Figure 3
Immunological and biochemical natures of the mAb. Panel A shows isotyping and subtyping results by immobilizing 
anti-human Igs as indicated. The binding profile of the mAb was subsequently revealed by biotinylated CD152-muIg and avidin-
peroxidase conjugates. Results indicate that the present mAb belongs to a type of IgG4λ. Panel B indicates the isoelectric point 
of the monoclonal IgG4λ anti-CD152 (lane 4 and 8), resolved by isoelectric focusing. Monoclonal human myeloma IgG1λ(lane 
2 and 6) and IgG4λ (lane 3 and 7) were run in parallel for comparison. The electrophoretic patterns were visualized by either 
Coomassie brilliant blue staining (lane 1–5) or immunoblot (lane 6–8) with anti-human IgG conjugated with peroxidase and 
FAST™ DAB. The calculated isoelectric points for human IgG1λ, IgG4λ and anti-CD152 mAb to be approximately in the range 
of 7.92–8.79, 5.76–6.52 and 7.87–8.41, respectively, based on the calibration against the linear regression of standard protein 
markers. Panel C outlines the affinity determination by IAsys. Surface plasmon resonance obtained at 25°C for increasing con-
centrations of anti-CD152 mAb on purified, unlabeled CD152-muIg. The straight line in the inset was obtained from the kobs 
plot versus ligated Ab concentration and yielded a kdiss (the intercept) of 16.81 and a kass value (the gradient) of 4.20 × 109. 
Therefore produced a Kd (kdiss/kass) of 4 × 10-9 M.
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CAA38313] with a measure of 92.13% similarity (Fig.
4B). High similarity to accessible V germline genes of
human but not other origins is indicative of complete
human Ab. Moreover, both VH (CDR2) and VL (CDR1
and CDR2) regions contained evidence of hyper muta-
tions away from the germline.
Little or no competition to B7- CD152 binding of 
γ4λhuCD152 both ex situ and in situ
Although the CDR2-containing epitope does not seem to
be involved in the binding of endogenous cognate ligands
(CD80 and CD86) and mAb engagement would not be
antagonistic, the epitope might present an allosteric site
for non-competitive inhibition. To investigate this possi-
bility, CTLA-4-muIg was immobilized onto wells and
either biotinylated CD80-muIg or CD86-muIg was used
as a binding ligand in the presence of γ4λhuCD152 or
BNI3, i.e., a CD152 antagonistic mouse IgG2a mAb [25].
Figure 5A shows, in contrast with the expected dose-
dependent inhibition of specific receptor binding by the
antagonistic BNI3, γ4λhuCD152 could not compete bind-
ing significantly with either CD80-muIg or CD86-muIg ex
situ. No clear difference in binding was found when com-
peting CD80-muIg or CD86-muIg was used in the bind-
ing of γ4λhuCD152 to CTLA-4-muIg (data not shown).
Surprisingly, high doses of γ4λhuCD152 mAb display
synergism with the natural ligand CD80 but not CD86
with a consequence up to 50% enrichment of CD80 bind-
ing to CTLA-4-muIg.
In order to investigate the binding effects more thor-
oughly, and to provide further information on their pos-
sible in situ relevance, it was assessed whether labeling of
endogenous CD152, a known rare Ag expressed only on
activated T cells, by different mAbs, influences the profile
of detection. A well-contrasted cytometric picture of total
CD152-binding and a clearly distinguishable concen-
trated pattern of labeling were evidenced on PHA/PMA-
activated T cells by using γ4λhuCD152, indicating a lower
nonspecific binding over the antagonistic BNI3 (Fig. 5B).
Partial deduced protein sequences of the mAb Figure 4
Partial deduced protein sequences of the mAb. Panel A represents the alignments of VH to known human VH 
sequences of the highest homology scoring. Panel B represents the alignments of VL to known human VL sequences of the 
highest homology scoring. FR, framework region; CDR, complementarity-determining region. Asterisks indicate amino acid 
identity to germline. Sequences are available from GenBank under accession numbers AY847516 (VH); AY847517 (VL); 
AB019439 (VH3–30 and VH3–33); BAC01778; S78058 and CAA38313. Homology searches were accomplished over the www 
using the program BLAST (Basic Local Alignment Search Tool) from NCBI (National Center for Biotechnology Information; 
Washington, DC.). A 12-aa CDRH3 sequenced Ala-His-Gly-Asp-Tyr-Gly-Arg-Asp-Gly-Met-Asp-Val was noted.
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Binding of γ4λhuCD152 and CD80/CD86 agonists to human CD152 are not mutually exclusive Figure 5
Binding of γ4λhuCD152 and CD80/CD86 agonists to human CD152 are not mutually exclusive. Panel A indicates 
the ligand competition assays that test the ability of monoclonal γ4λhuCD152 (solid line) and BNI3 (dashed line) anti-CD152 to 
compete for the CD80/CD86 and CD152 interactions. Biotinylated CD80-muIg or CD86-muIg plus indicated increasing con-
centrations of the mAbs (10-3-10 µg/mL) were incubated in microtiter wells coated with purified CD152-muIg. Bound CD80/
CD86 was detected with avidin-peroxidase conjugate and a peroxidase substrate. The data shown are representative of three 
experiments. Panel B illustrates the determination of in situ CD152 expression before and after PHA/PMA stimulation. Parafor-
maldehyde-fixed cells were first labeled with PE-anti-CD3 and BNI3 or γ4λhuCD152, and then incubated with FITC-conjugated 
anti-mouse IgG2a or anti-human IgGs, respectively. The percentage of each stained population after stimulation is denoted.
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Hence, non-ligand competitive γ4λhuCD152 could be
used as a new and refined probe which should be useful
for sensitive assay and localization of CD152 both in situ
and ex situ.
Discussion
Previously published techniques for in vitro immuniza-
tion required pre-treatment of PBMC with chemotoxic
agents, such as L-leucyl-L-leucin methyl ester hydrobro-
mide (LeuLeuOMe), in order to prevent the "suppressing
populations" dominating the response [23]. Unfortu-
nately, residual cytotoxicity and relative redundancy of
LeuLeuOMe interferes with subsequent survival and pep-
tide-driven stimulation and therefore the process requires
careful timing for the greatest effectiveness. It was found
that when Abs were used as more selective reagents to spe-
cific removal of CD56+ and IL-10+ cells, no LeuLeuOMe
pretreatment is necessary [see Additional File 1]. Advan-
tages of this improved procedure over the conventional
procedure are clearly illustrated in the present study, not
only in the reduction in sample manipulation, but also in
successfully targeting human Ab responses to a pre-deter-
mined epitope without the use of experimental animals or
sensitized donors. We believe this first reported human
mAb directed against a self physiological receptor also sig-
nifies a constructive method for recruiting and unleashing
the responses to physiological receptors that may not be
recognized by donors' own immune system in vivo.
We found that the ex situ CD152 binding of CD80
increased with the increasing concentration of
γ4λhuCD152 (Fig. 5A). Whether this observation also
applied in situ is yet to be verified. However, human non-
antagonistic anti-CD152 scFv fragments, obtained from a
synthetic phage library, were indeed documented to syn-
ergize with CD80–CD152 but not CD86–CD152 associa-
tion [26], although to a less extent as compared with the
present study. As described above, the CDR2-like Met 55-
cored epitope, 54YMMGNELTFLDDSIC68, on CD152 may
not be directly involved in the binding of CD80 but the F-
G (CDR3-like) and B-C (CDR1-like) loops provide direct
contacts and additional stabilization to CD80, respec-
tively [18,20]. Thus CD80–CD152 binding enhancement
by γ4λhuCD152 (and possibly mAbs specific to this par-
ticular CDR2-like site) may be attributed to an extended
protrusion of the CDR3-like region that facilitates CD80
engagement, or to a further segmentation that fixes the
relative orientation of the binding domains for an addi-
tional spacing selectivity. These possibilities are not mutu-
ally exclusive.
Despite the fact that the present mAb was derived from
healthy human donors, several mouse mAbs with similar,
but not identical, binding specificities were previously
available in literature. For example, mAbs with agonist- or
antagonist-like activities against human CD152 were
obtained from mice immunized with the recombinant
receptor or mitogen-activated human PBMCs in 1995
[27] and 1999 [25]. In the earlier case, the epitopes
responsible for the functional activity of the Abs were
finely identified. This analysis documented that the
CDR2-adjacent epitope (60LTFLDD65) and the conforma-
tional or CDR3 epitope (102PPYYL106) are responsible for
agonist- and antagonist-like activities, respectively. In
addition, using a bispecific tandem single-chain variable
fragment recognizing 59ELT61 and 66SICT69, another study
has revealed a likely CD152 inverse agonist of Ab nature
[21]. Ultimately systematic studies are needed to clarify
the pharmacological effects of the present human mono-
clonal IgG4λ with an epitope of a comparable stride
(59~69 vs. 54~68).
A conspicuous feature of the present findings is that it is
now possible to screen and construct isotype-switched,
high affinity human mAbs with pre-defined specificities
than previously possible. Consequently, mAbs are able to
mimic ligands action commonly found in small synthetic
molecules and to facilitate comprehensive receptor-based
drug designs. Another peculiarity, as Figure 3A shows the
simultaneous presence of IgG4Fc and Cλ human Ig chains
associated with the specificity, is that γ4λhuCD152 can be
described as a comparable if not a fundamentally authen-
tic human IgG4. Because IgG4 does not activate the com-
plement cascade and it is much more compact than other
IgG's [28], accentuating its advantages for acting in the
immunological synapse where a spatial limitation is
applied [29]. Although the current example comes from
CD152, obviously it can also apply to other biological
receptors and their cognate ligands.
Conclusion
In the present study, we started with an improved, more
selective  in vitro immunization protocol and worked
toward fully human mAbs against a representing self Ag,
CD152. Considerable progress has thus been made in this
area as a result of a novel human IgG4λ mAb against
CD152. The application of such a mAb with designated
CDR2 specificity may impact upon and favor CD152
detection and/or isolation of human CD4+CD25+CD152+
regulatory T cells [30]. The present study also opens up the
possibility of probing and perhaps controlling T cell acti-
vation using highly specific, less immunogenic Ig pro-
teins. Further deciphering the biological functions
mediated by γ4λhuCD152 may lead to a greater under-
standing of the regulation and differentiation of immune
responses.BMC Biotechnology 2007, 7:51 http://www.biomedcentral.com/1472-6750/7/51
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Methods
Culture materials Ag and Ab reagents
The culture medium used was RPMI-l640 (HyClone,
Logan, UT), supplemented with 1 × non-essential amino
acids (Life Technologies, Gaithersburg, MD), 10% fetal
bovine serum (FBS; Life Technologies) and 50 µg/ml of
gentamycin and kanamycin (Sinton Chemical & Pharma-
ceutical, Hsinchu, Taiwan). Purified and biotinylated
human CD152-murine Ig fusion protein (CD152-muIg),
CD80-muIg and CD86-muIg (Ancell, Bayport, MN) were
used in Ag-specific and competing enzyme-linked immu-
nosorbent assay (ELISA), together with peroxidase-
labeled goat antibodies against human IgG and IgM
(Zymed Laboratories, South San Francisco, CA) or avidin
horseradish peroxidase (eBioscience, San Diego, CA) as
the reporting system. The fluorochrome-conjugated
mouse mAb against human IgGs and human CD3
(UCHT1; mouse IgG1), together with rat mAb against
mouse IgG2a were commercially available from Becton
Dickinson Immunocytometry Systems (San Jose, CA) and
Abcam (Cambridge, UK). The anti-CD3 (OKT3; mouse
IgG2a) used for T cell activation and the antagonistic anti-
CD152 (BNI3; mouse IgG2a) were purchased from eBio-
science and Abcam, respectively.
Preparation of human PBMC
Plasma and buffy coat samples from healthy routine
blood donors, screened negative for HIV-1/2, HTLV-I/II,
HCV, HBsAg and containing normal levels of alanine
transferase (ALT), were obtained from the Tainan and
Hualien Blood Centers, Taiwan Blood Services Founda-
tion. Written informed consents were obtained from five
repeatedly-healthy regular blood donors after an explana-
tion of the nature, purpose, and potential risks of the
study and then 230 ml of whole blood was used for the
purpose of site-directed in vitro immunization. PBMC's
were isolated by density centrifugation on Ficoll-Paque
(GE Healthcare Bio-Sciences, Uppsala, Sweden) as
described elsewhere.
Magnetic cell purification and depletion
PBMC's were magnetically labeled with CD45RO MACS®
microbeads (Miltenyi Biotec, Bergisch Gladbach, Ger-
many) then separated by a VarioMACS™ (Miltenyi) instru-
ment according to the manufacturer's instructions. The
purified CD45RO+ T cells were cultured at a density of 2 ×
106 cells/ml in the culture medium supplemented with 50
µM 2-mercaptoethanol and 10 µg/ml pokeweed mitogen
(PWM; Sigma, St. Louis, MO). After 24 h, cells were
removed by 400 × g centrifugation to collect CD45RO+ T
cell replacing factor. Removal of cytotoxic cell popula-
tions, which inhibit in vitro immunization [23], was simi-
larly performed by using colloidal super-paramagnetic
microbeads conjugated to monoclonal anti-human CD8
and anti-CD56 antibodies (Miltenyi). Removal of IL-10-
producing cells was achieved by using rat anti-human IL-
10 (SouthernBiotech, Birmingham, AL) and goat anti-rat
IgG microbeads (Miltenyi).
Site-directed in vitro immunization
Cytotoxic cell-depleted PBMCs were immunized in vitro
based on a previously described two-step principle [6].
Primary immunization was performed by incubating the
cells for 6 days in a medium containing 10 nM of the het-
erotopic peptide Ag (QYIKANSKFIGITELAATYMM-
GNELTFLDDSICT; Fine Research Biochem, Taoyuan,
Taiwan), 50 µM 2-mercaptoethanol, 10% heat-inacti-
vated human serum, 0.05 ng/ml recombinant human (rh)
IL-2 (eBioscience), and 25% (v/v) CD45RO+ T cell replac-
ing factor. For secondary immunization, 3 × 107 primary-
immunized cells were mixed with the peptide in a flask
that had been immobilized overnight with 5 mg/ml of
CD40L (CD154; eBioscience) together with 1 × 107
QYIKANSKFIGITEL (Fine Research Biochem)-stimulated
CD4+ T cells and 5 ng/ml rh IL-15 (eBioscience). The cells
were cultured for 3–5 days in a medium supplemented
with 5% human serum, 50 mM 2-mercaptoethanol and
10 nM heterotopic peptide Ag. The significance of differ-
ences between treated and control cultures was estab-
lished by using Student's t test. A P value of less than 0.05
was considered statistically significant.
Epstein-Barr virus (EBV) infection, ELISA and somatic cell 
hybridization
The in vitro immunized cells were infected with EBV by
virus-containing supernatant derived from the EBV-pro-
ducing marmoset cell line B95-8 (American Type Culture
Collection, ATCC CRL 1612; kindly provided by Dr. L.-F.
Sheu, Tri-Service General Hospital, Taipei). The infected
cells were seeded at 105/well in 96-well plates together
with mytomycin (Kyowa Hakko Kogyo, Tokyo, Japan)-
treated PBMC as feeder cells (104/well) for the establish-
ment of lymphoblastoid cells and screened for Abs by
ELISA.
Ag-specific ELISA was performed by coating 0.25 µg/ml
purified rhCD152-muIg, 0.5 µg/ml monoclonal mouse
IgG2a (mIgG2a; Ancell), 1 µg/ml bovine serum albumin
(BSA; Sigma) or 1 µg/ml tetanus toxoid (TT; ADImmune,
Taichung, Taiwan) onto microtitre plates overnight at
4°C. Culture supernatants were diluted to the desired
level in 10 mM sodium phosphate buffer (pH 8.0), con-
taining 0 5 M sodium chloride and 0.1% Tween-20.
Coated plates were incubated with diluted culture super-
natants, washed, incubated with peroxidase-labeled goat
antibodies against human IgG and IgM and developed
(15 min) by addition of 100 µl of the chromogenic sub-
strate o-phenylaenediamine (OPD) (Sigma). The reaction
was stopped after 30 min by adding 1 M sulphuric acid,
and the absorbances were read at 490 nm.BMC Biotechnology 2007, 7:51 http://www.biomedcentral.com/1472-6750/7/51
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Somatic cell hybridization was generated by electrofu-
sion. Briefly, Ag-specific EBV-infected lymphoblastoid
cells were fused with heteromyeloma cells [22] in an isot-
onic medium (280 mM sorbitol, 0.5 mM magnesium ace-
tate, 0.1 mM calcium acetate and 1 mg/ml BSA; pH6.9–
7.1). Cell fusion was induced by high-voltage pulses using
a BTX Electro Cell Manipulator ECM 2001 (Harvard
Apparatus, Holliston, MA). Ag-specific hybrids were
selected and cloned by limiting dilution.
Epitope mapping
To define the specific epitope of human CD152 recog-
nized by the mAb, we used peptide arrays (Genesis Bio-
tech, Taipei, Taiwan and Fine Research Biochem,)
containing in-situ synthesized peptides immobilized on
special membrane. In brief, 1 µg/mL of protein A (Proteus
MIDI kit, Pro-Chem, Littleton, MA)-purified mAb was
incubated by shaking in room temperature for 2 h. After
washing, the membrane-bound mAb was then visualized
by diluted anti-human IgG conjugated with peroxidase
(Jackson ImmunoResearch Laboratories, West Grove, PA)
and FAST™ DAB (Sigma). The amount of bound mAb was
calculated by Image-Pro Plus 4.5 software (Media Cyber-
netics, Silver Spring, MD) on the scanned images.
Flow cytometry analyses
The surface expression of the CD152 epitope recognized
by the present mAb was analyzed using two-color flow
cytometry on mitogen-stimulated PBMC's by a FACSCal-
iber™ flow cytometer and CellQuest™ software (Becton
Dickinson Immunocytometry Systems). 2 × 106 isolated
PBMC's were resuspended in supplemented culture
medium and treated with either anti-human CD3 (OKT3;
final concentrations in culture 10 µg/ml, eBioscience),
concanavalin A (Con A; final concentrations in culture 10
µg/ml, Sigma), 10 µg/ml phytohemagglutinin (PHA; final
concentrations in culture 1 µg/ml, GE Healthcare Bio-Sci-
ences), a combination of phorbol 12-myristate acetate
(PMA; 50 ng/ml, Sigma) + ionomycin (1 µM, Sigma) or a
combination of PHA (1 µg/ml) + PMA (50 ng/ml). Loga-
rithmically amplified fluorescence data were collected on
10,000 CD3+ cells. All flow cytometry staining procedures
were performed at 4°C in cytometry buffer. For extracellu-
lar detection of CD152, activated cells were first surface
stained with the mAb or isotype control at 4°C, followed
by anti-human IgG-FITC and anti-CD3-PE (Becton Dick-
inson) staining.
RT-PCR assays for deduction of Ab primary structures
The Ab primary structures were deduced by cDNA
sequencing from cloned trioma cells. Briefly, poly(A)+
RNA was isolated from by using Dynabeads®  mRNA
DIRECT™ Kit (Invitrogen, Carlsbad, CA). Purified mRNA
was then employed as the reaction template in reverse
transcription polymerase chain reactions (RT-PCR). The
RT-PCR was carried out with Titan One Tube RT-PCR Sys-
tem™ (Roche Diagnostics Corporation, Indianapolis, IN).
PCR primers (1 µM) used to amplify human VH and VL
were the HuVH-JH set (forward: 5'-caggt caact taagg gagtc
tgg-3' and reverse: 5'-tgaga gacgg tgacc gtggt ccc-3') and the
HuVλ set (forward: 5'-tccta tgtgc tgact cagcc acc-3' and
reverse: 5'-accta ggacg gtgac cttgg tccc-3'), respectively. The
37 temperature cycles include: one 2-min denature cycle
of 94°C; 35 cycles of 3-min denaturation at 94°C, 1-min
annealing and extension at 68°C; and a final 10-min
extension cycle of 68°C. Single banded PCR fragments
were seperated by 2% agarose gel electrophoresis. The
DNA fragments were purified from gel by Wizard PCR
Preps DNA purification system (Promega, Madison, WI).
The purified products were subjected to nucleotide
sequencing. Sequences were verified (Molecular Clinical
Diagnostic Laboratory, Dr. Chip Biotechnology, Inc., Tai-
pei, Taiwan) and converted to corresponding amino
acids.
Isoelectric point electrophoresis and affinity analyses
The isoelectric point of secreted IgG was examined by
Novex IEF Gels (Invitrogen). Desalted and dialyzed pro-
tein samples were mixed with IEF sample buffer at 1:1 (v/
v) ratio. Electrophoresis was performed at following con-
dition: 100 V for 1 h, 200 V for 1 h and 500 V for 30 mins.
After electrophoresis, gels were removed from gel cassette
and fixed in 10% trichloroacetic acid for 30 mins. Fixed
gel was developed by Coomassie brilliant blue staining or
silver staining. The broad-range calibration kit for pI
determinations (#17-0471-01, pH 3–10; GE Healthcare
Bio-Sciences) was included as the standard. The isoelectric
point of interested proteins was calculated by Phoretix 2D
Elite software (Nonlinear Dynamics, Durham, NC).
The affinity of the mAb was determined against CD152-
muIg with an IAsys optical biosensor (Affinity Sensors,
Cambridge, UK) according to the manufacturer's instruc-
tions. Briefly, 200 µg/ml dialyzed and diluted CD152-
muIg was immobilized on the activated surface of car-
boxymethyl dextran cuvettes in 10 mM of sodium acetate
buffer at pH 3.8. After conditioning with 10 mM HCl,
immobilization of 2 mg/mL CD152-muIg resulted in a
response of 1100 arc sec. This represents the highest
immobilization response for CD152 and gives a ligate
binding capacity (Rmax) of 300 arc sec. Serial dilutions of
the mAb in PBS, i.e. 1.34 × 10-9 M, 6.70 × 10-9 M, 1.34 ×
10-8 M, 2.68 × 10-8 M and 5.36 × 10-8 M, were added to the
CD152-coated cuvettes (final volume, 50 µl). Affinity
constants (Kd) were calculated from these measurements
as kdiss/kass by using the FASTFIT® program provided by the
manufacturer.
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CTLA-4- Cytotoxic T lymphocyte antigen-4.
IEF- Isoelectric focusing.
Ig- Immunoglobulin.
Kd- Equilibrium dissociation (affinity) constant.
LeuLeuOMe- L-leucyl-L-leucin methyl ester hydrobro-
mide.
mAb- Monoclonal antibody.
PBMC- Peripheral blood mononuclear cells.
PBS- Phosphate buffered saline (20 mM phosphate
buffer, pH 7.2 containing 145 mM NaCl).
VH- The variable regions of Ab heavy chain.
VL- The variable regions of Ab light chain.
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